Föreläsningar och seminarier OnkPat Friday Seminar: Precision Therapy for Mesothelioma – seeking synthetic lethality

Värd: Katalin Dobra, institutionen för onkologi-patologi

Läs mer om Dean Fennell på den engelska sidan.

Utvalda publikationer

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.
Fennell DA, Hill K, Zhang M, Poile C, Ewings S, Baitei EY, Dzialo J, Nusrat N, Rogel J, Faulkner D, Ottensmeier C, Califano R, Hanna GG, Danson S, Steele N, Nye M, Johnson L, Mallard K, Lord J, Middleton C, Szlosarek P, Chan S, Darlison L, Wells-Jordan P, Richards C, Harber J, Bzura A, Spicer J, Pritchard C, Kamata T, Hahne JC, Jama M, Hollox EJ, Lester JF, Luo JL, Zhou Z, Yang H, Zhou H, Klampatsa A, Griffiths GO
Nat Commun 2025 Jul;16(1):6688

A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.
Zhang M, Bzura A, Baitei EY, Zhou Z, Spicer JB, Poile C, Rogel J, Branson A, King A, Barber S, Kamata T, Dzialo J, Harber J, Greystoke A, Nusrat N, Faulkner D, Sun Q, Nolan L, Hahne JC, Scotland M, Walter H, Darlison L, Morgan B, Bajaj A, Brookes C, Hollox EJ, Lubawska D, Jama M, Griffiths G, Nakas A, Kutywayo K, Luo JL, Klampatsa A, Cooper A, Halder K, Wells-Jordan P, Zhou H, Dudbridge F, Thomas A, Richards CJ, Pritchard C, Yang H, Barer M, Fennell DA
Nat Commun 2024 Aug;15(1):7187

Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
Fennell DA, King A, Mohammed S, Greystoke A, Anthony S, Poile C, Nusrat N, Scotland M, Bhundia V, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Bajaj A, Richards C, Wells-Jordan P, Thomas A, 
Lancet Oncol 2022 Mar;23(3):374-381

Pleural mesothelioma.
Fennell DA, Sekido Y, Baas P, Husain AN, Curioni-Fontecedro A, Lim E, Opitz I, Simone CB, Brims F, Wong MC
Nat Rev Dis Primers 2025 Aug;11(1):56

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.
Gibson V, Dzialo J, Messier T, Bzura A, Poile C, Rogel J, Hahne JC, Habibovic A, Stead S, Saaman A, Blyth KG, Szlosarek PW, Lord S, Thistlethwaite F, Zhang M, Nakas A, Wells-Jordan P, Kutywayo K, Butnor KJ, Heintz NH, Naumov GN, Dungey M, Colomina JH, Aktas B, Dulloo S, Spicer J, Fennell DA, Cunniff B
Nat Commun 2026 Jul;17(1):

Accelerating innovations in systemic therapy for pleural mesothelioma.
Fennell DA, Bzura A
Nat Cancer 2022 Aug;3(8):902-904